paper_id,claim,figure_id,title,caption,local_image_path,url
PMC5488108,"Safety was assessed descriptively.Statistical Analysis
Exploratory, descriptive analyses of demographic, safety, and efficacy data were planned based on the treated set (all patients who were dispensed medication and were documented to have taken ≥1 afatinib dose), with two subgroups divided by previous TKI exposure.Results
Patients
From July 2012 to March 2014, 371 patients were enrolled and 322 patients were treated with ≥1 afatinib dose (Fig. 1).",PMC5488108_figure_1,Fig. 1.,"Disposition of patients (enrolled set).a
EAP expanded access program, AE adverse event. a Enrolled set included all patients who signed the informed consent. b Transition to commercially available drug",./data/PMC5488108/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f47/5488108/53531b8dcd5e/40487_2017_43_Fig1_HTML.jpg
PMC5488108,"Results
Patients
From July 2012 to March 2014, 371 patients were enrolled and 322 patients were treated with ≥1 afatinib dose (Fig. 1).",PMC5488108_figure_1,Fig. 1.,"Disposition of patients (enrolled set).a
EAP expanded access program, AE adverse event. a Enrolled set included all patients who signed the informed consent. b Transition to commercially available drug",./data/PMC5488108/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f47/5488108/53531b8dcd5e/40487_2017_43_Fig1_HTML.jpg
PMC5488108,"Patients
From July 2012 to March 2014, 371 patients were enrolled and 322 patients were treated with ≥1 afatinib dose (Fig. 1).",PMC5488108_figure_1,Fig. 1.,"Disposition of patients (enrolled set).a
EAP expanded access program, AE adverse event. a Enrolled set included all patients who signed the informed consent. b Transition to commercially available drug",./data/PMC5488108/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f47/5488108/53531b8dcd5e/40487_2017_43_Fig1_HTML.jpg
PMC5488108,"From July 2012 to March 2014, 371 patients were enrolled and 322 patients were treated with ≥1 afatinib dose (Fig. 1).",PMC5488108_figure_1,Fig. 1.,"Disposition of patients (enrolled set).a
EAP expanded access program, AE adverse event. a Enrolled set included all patients who signed the informed consent. b Transition to commercially available drug",./data/PMC5488108/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f47/5488108/53531b8dcd5e/40487_2017_43_Fig1_HTML.jpg
